For part XIV see \[1\].

Introduction
============

Cinnamic acid derivatives are known as biologically active compounds. Cinnamic acid and its hydroxy derivatives bearing a phenolic moiety such as coumaric, caffeic, ferulic, sinapinic, and chlorogenic acids \[[@R2]--[@R6]\], simple cinnamic acid derivatives (esters, amides, etc.), and prenylated cinnamates \[[@R4]\], have been proved to be effective as antioxidants \[[@R2],[@R7]\], radical scavengers \[[@R2]\], antimicrobials \[[@R2],[@R7]--[@R8]\], antibacterials \[[@R2]\], antivirals \[[@R2],[@R7]\], and fungicides \[[@R2],[@R7]--[@R8]\]. Cinnamic derivatives have also been recognized as active agents against tuberculosis and malaria \[[@R3],[@R7]\], cardiovascular diseases \[[@R3]\], and cancer \[[@R4]\]. Cinnamates show depigmenting \[[@R4]\], antidiabetic, antihyperglycemic, anticholesterolemic, anti-inflammatory, hepatoprotective, CNS depressant, anxiolytic, and cytotoxic activity \[[@R7]\]. Cinnamate esters have been used as effective UV filters (especially in UVB region, 280--320 nm) in cosmetics \[[@R7],[@R9]\], and as fragrance materials \[[@R7]\]. Fragrance material reviews on cinnamic acid derivatives were extensively described in *Food and Chemical Toxicology* (especially in 2007) and in *Food and Cosmetics Toxicology* (in the 70s). The most recent reviews in this series were published in 2011 \[[@R10]--[@R11]\].

Cinnamic acid derivatives can be synthesized using Perkin, Knoevenagel, Claisen \[[@R7]\], and Wittig \[[@R12]\] condensation reactions. Since the discovery of catalytic coupling reactions, cinnamic derivatives have also been obtained using the Mizoroki--Heck cross-coupling reaction between aryl halides and an olefin \[[@R7],[@R13]--[@R17]\]. Because cinnamates themselves are also olefins, they can serve as cinnamic substrates to synthesize more complex cinnamates \[[@R18]--[@R19]\]. Cinnamic acid derivatives are also formed when saturated aliphatic acids (instead of unsaturated ones as acrylates) are reacted with simple aromatic compounds (as benzene) in the presence of palladium(II) chloride \[[@R20]\]. Due to the important biological activity of cinnamates, the incorporation of a spin label moiety, particularly a nitroxyl fragment, is interesting, because it allows for the study of cinnamates using spin labeling methods.

To accomplish the synthesis of cinnamates bearing a nitroxyl moiety, we applied a Mizoroki--Heck cross-coupling reaction, using 4-acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**, an olefin component bearing a nitroxyl moiety), recently applied in the Morita--Baylis--Hillmann reaction \[[@R21]\]. The use of nitroxides in cross-coupling reactions is described only in a limited number of papers \[[@R22]--[@R32]\]. To the best of our knowledge, there are no systematic studies on the use of nitroxides in the Mizoroki--Heck cross-coupling reaction.

Despite the observation that an unpaired electron in nitroxides does not participate in organic reactions has been well known since the beginning of the nitroxide progress in 60\'s \[[@R33]\] the reactions of nitroxides involving an unpaired electron are also recognized (e.g., reductions, acidic medium, carbene addition, etc.). Because we would like to check the possibility of performing the Mizoroki--Heck cross-coupling reaction with nitroxides, herein the synthesis of cinnamates bearing a nitroxyl moiety is presented using aryl iodides as exemplary test compounds.

Results and Disscusion
======================

4-Acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**) was obtained in 90--95% yield by the reaction of acryloyl chloride (**2**) with 2,2,6,6-tetramethyl-4-piperidinol-1-oxyl (**1**) in the presence of triethylamine \[[@R21],[@R34]--[@R36]\].

The couplings of 4-acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**) with iodobenzene (**4a**) and 4-methyliodobenzene (**4b**) were used as the test reactions to check the effectiveness of various palladium catalyst systems.

The use of Pd(OAc)~2~/Ph~3~P/Bu~3~N \[[@R37]\] resulted in a low yield of the target products. No products were obtained when other catalyst systems: Pd\[PPh~3~\]~4~ \[[@R38]\], Pd(CF~3~COO)~2~/tri(2-furylphosphine) and Pd(acetylacetonate)~2~/tri(2-furylphosphine) \[[@R39]\] were tested. As a rule, unreacted **3** was identified, and always isolated. A number of unidentified products were detected by means of TLC.

Finally, the target cinnamates bearing a nitroxyl moiety (**5a**--**i**) were obtained using the coupling of 4-acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**) with a series of iodobenzene derivatives (**4a**--**i**) in the presence of palladium(II) acetate coordinated with tri(*o*-tolyl)phosphine ligand immobilized in a polyurea matrix (commercially available as PdEnCatTOTP30™) \[[@R40]--[@R45]\] ([Scheme 1](#C1){ref-type="fig"}, [Table 1](#T1){ref-type="table"}).

![Cinnamates bearing a nitroxyl moiety **5a**--**i** from 4-acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**) and iodobenzene derivatives; (i) CH~2~=CH--COCl (**2**), NEt~3~, benzene, 90--95%; (ii) R--Ar--I **4a**--**i**, PdEnCat TOTP30, Bu~4~N^+^AcO^−^, toluene, 80--100 °C, 30--100%.](Beilstein_J_Org_Chem-11-1155-g003){#C1}

###### 

Cinnamates bearing a nitroxyl moiety (**5a**--**i**).

  ---------- ----------------- ----------------------------- --------------------- ------------- -----------
  Compound   R                 Reaction temperature \[°C\]   Reaction time \[h\]   Yield \[%\]   mp \[°C\]
                                                                                                 
  **5a**     H                 80                            22                    42.4          97--98
  **5b**     4-CH~3~           100                           2--20                 30.4          oil
  **5c**     3,4-diCl          80                            25                    62.7          118--120
  **5d**     4-CH~3~O          85                            24                    75.8          70--74
  **5e**     2-NO~2~           90                            20                    76.4          107--110
  **5f**     3-NO~2~           80--90                        20                    99.9          121--123
  **5g**     4-NO~2~           80--85                        23                    55.3          148--149
  **5h**     2-CH~3~-4-NO~2~   80--85                        27                    88.3          109--112
  **5i**     2-Cl-4-NO~2~      80--85                        27                    56.2          107--110
  ---------- ----------------- ----------------------------- --------------------- ------------- -----------

The best results were obtained when an electron-withdrawing substituent NO~2~ was present in the benzene ring. The reactions of iodobenzene bearing 4-F, 4-CF~3~, 2,4-diNO~2~ substituents were unsuccessful. In the case of the reaction of **4b** leading to the cinnamate **5b**, the results were unrepeatable (the times and yields of the reactions). Unidentified impurities together with the product **5b** were observed (^13^C NMR).

No products in the case of 4-F, 4-CF~3~, 2,4-diNO~2~ substituents and unrepeatability in the case of cinnamate **5b** can be caused by means of a type of a heterogeneous catalyst which is immobilized on a solid support. In addition to the widely highlighted unquestionable advantages of immobilized, heterogeneous catalysts (easy separation from the reaction mixture and the possibility of re-use), such catalysts are rigidly anchored on a carrier and may cause hindered interaction with substrates. Some of the catalytic sites may be buried within the polymer matrix and cannot participate in the reactions \[[@R46]\]. This disadvantage may cause various unwanted effects. As examples, no clear relationship between the structures of the aryl iodides and the yields were observed, as described in \[[@R47]\], or a catalyst that accepts only electron-rich aryl iodides \[[@R48]\].

The structure of the synthesized cinnamates bearing a nitroxyl moiety were confirmed using EIMS, ESIMS, HREIMS, HRESIMS, ^1^H NMR, ^13^C NMR, and IR spectra (Experimental part and [Supporting Information File 1](#SD1){ref-type="supplementary-material"}). Recording of the NMR spectra of the nitroxides required removing of the unpaired electron. This was achieved by adding a drop of a reducing agent -- in fact the spectra of the corresponding hydroxylamines were recorded. In this research phenylhydrazine has been used \[[@R49]--[@R50]\], however, sometimes using of hydrazobenzene \[[@R51]--[@R52]\] or pentafluorophenyl hydrazine \[[@R35]\] as reducing agents have been reported, as well.

The *E* geometry of **5a**--**i** was confirmed by ^1^H NMR spectroscopy. The values of the coupling constants of the doublets visible in the ^1^H NMR spectra of **5a**--**i** belonging to the double bond of **5a**--**i** remain in the range 15.5--16.0 Hz. These values confirm the *E* geometry of **5a**--**i**. In [Table 2](#T2){ref-type="table"} the shifts and the coupling constants of the double bond are presented.

###### 

Chemical shifts and coupling constants of the hydrogen atoms belonging to the double bond of **5a**--**i**: OOC--CH^(B)^=CH^(D)^--C~6~H~4(3)~--R.

  ------- ----------------- ------------------ ------------------ -----------------
  **5**   R                 δ H^(B)^ \[ppm\]   δ H^(D)^ \[ppm\]   *J* ~DB~ \[Hz\]
                                                                  
  **a**   H                 6.41               7.67               16.0
  **b**   4-CH~3~           6.35               7.64               15.8
  **c**   3,4-diCl          6.38               7.40               15.5
  **d**   OCH~3~            6.28               7.62               16.0
  **e**   2-NO~2~           6.33               8.10               16.0
  **f**   3-NO~2~           6.53               7.69               16.0
  **g**   4-NO~2~           6.52               7.32               16.0
  **h**   2-CH~3~-4-NO~2~   6.42               7.90               15.9
  **i**   2-Cl-4-NO~2~      6.51               8.03               16.0
  ------- ----------------- ------------------ ------------------ -----------------

The substituent in 2-position of the cinnamates **5e**, **5h**, **5i** causes the noticeable shift of H^D^ hydrogen to the lower field. This observation suggests that conformation X, where the substituent in 2-position and the H^D^ atom are placed close to each other, is more populated than conformation Y ([Fig. 1](#F1){ref-type="fig"}).

![Conformations of the substituent in 2-position of the cinnamates **5e**, **5h**, **5i**.](Beilstein_J_Org_Chem-11-1155-g002){#F1}

For cinnamate **5f** (3-NO~2~), the direct measurement of the chemical shift of the hydrogen atom H^D^ (OOC-CH^(B)^=C**H** **^(D)^**-C~6~H~4~-NO~2~ ^(m)^) was not possible, due to the presence of more than one equidistant (16 Hz) peak close to 7.5 ppm. Irradiation of H^B^ (δ 6.53 ppm) allowed to distinguish the signal of H^D^ at 7.69 ppm.

A molecular peak was present in all mass spectra of the synthesized products **5a**--**5i**. Except in the case of **5c**,**i** it was clearly visible (5--25%). In all of the mass spectra, the abundant peak of the cinnamyl acyl cation ArCH=CHCO^+^ was present. This was a base peak in the case of **5a,d**.

Characteristic signals for 4-*XO*-substituted 2,2,6,6-tetramethylpiperidine-1-oxyl moiety (TEMPOL, TEMPOL esters, etc.) were observed at *m*/*z* = 154, 124, 109 \[[@R53]--[@R54]\]. The signals at *m*/*z* 124, and 109 are abundant. The signal at *m*/*z* 154 was assigned to the structure, resulting from elimination of a XOH from the position 4 and 3 of the piperidine ring. The subsequent loss of a NO group (M = 30) and a CH~3~ group (M = 15), respectively, generates ions at *m*/*z* 124 and 109 ([Scheme 2](#C2){ref-type="fig"}). The peaks at *m*/*z* 154, 124 and 109 were thoroughly analyzed for the acrylate **3**, as an example.

![The formation of the fragment ions at *m*/*z* 154, 124, 109.](Beilstein_J_Org_Chem-11-1155-g004){#C2}

Proposed elemental composition of the fragmentation ions at *m*/*z* 154, 124, 109 for the acrylate **3** were confirmed by the measurement of their exact mass:

-   *m*/*z* 154 (calculated C~9~H~16~NO: 154.12319, found: 154.12390),

-   *m*/*z* 124 (calculated for C~9~H~16~: 124.12520, found: 124.12515),

-   *m*/*z* 109 (calculated for C~8~H~13~: 109.10173, found: 109.10079).

The signal at *m*/*z* 124 is the base one in the case of **5b**,**e**,**g**,**h**, and that at *m*/*z* 109 in the case of **5c**,**f**,**i**. The *m*/*z* values and relative intensities of the discussed signals are collected in [Table 3](#T3){ref-type="table"}.

###### 

The relative intensities of the molecular, cinnamic acyl, *m*/*z* 154, *m*/*z* 124, and *m*/*z* 109 ions.

  ------- ----------------------- ------------------------------------------ -------------- -------------- --------------
  **5**   M \[*m*/*z* (int.%)\]   ArCH=CHCO \[*m*/*z* (int.%)\]              *m*/*z* 154\   *m*/*z* 124\   *m*/*z* 109\
                                                                             int. %         int. %         int. %

                                                                                                           

  **a**   302 (10)                131 (100, C~6~H~5~CH=CHCO)                 27             89             69

  **b**   316 (24)                145 (91, 4-CH~3~C~6~H~4~CH=CHCO)           46             100            75

  **c**   370 (2)                 199 (64, 3,4-Cl~2~CH~3~C~6~H~3~CH=CHCO)    16             88             100

  **d**   332 (19)                161 (100, 4-CH~3~OC~6~H~4~CH=CHCO)         20             61             44

  **e**   347 (23)                176 (63, 2-NO~2~C~6~H~4~CH=CHCO)           25             100            87

  **f**   347 (5)                 176 (85, 3-NO~2~C~6~H~4~CH=CHCO)           13             83             100

  **g**   347 (19)                176 (89, 4-NO~2~C~6~H~4~CH=CHCO)           19             100            90

  **h**   361 (15)                190 (74, 2-CH~3~-4-NO~2~C~6~H~4~CH=CHCO)   29             100            82

  **i**   381 (2)                 210 (41, 2-Cl-4-NO~2~C~6~H~4~CH=CHCO)      15             89             100
  ------- ----------------------- ------------------------------------------ -------------- -------------- --------------

In conclusion, we showed that 4-acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**) can be used as starting material in the synthesis of new cinnamates containing a nitroxyl group in a Mizoroki--Heck cross-coupling reaction.

Experimental
============

General
-------

The protocols for the synthesis of 4-acryloyloxy-2,2,6,6-tetramethylpiperidine-1-oxyl (**3**) and its precursor 2,2,6,6-tetramethyl-4-hydroxypiperidin-1-oxyl (TEMPOL, **1**) were done according to \[[@R21]\]. The identity of **3** was additionally confirmed by ^1^H and ^13^C NMR performed in the presence of PhNHNH~2~. ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, in the presence of PhNHNH~2~) 1.23 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~), 1.24 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* **~3~**)(CH~3~)), 1.65 (t, *J* = 11.8 Hz, 2H, *H*HC-CH(O-)-CH*H*), 1.96 (ddt, *J* = 12.8 Hz, *J* = 4.2 Hz, *J* = 1.5 Hz, 2H, H*H*C-CH(O-)-C*H*H), 5.13 (tt, *J* = 11.2 Hz, *J* = 4.3 Hz, 1H, C*H*-OC(=O)), 5.81 (dd, *J* = 10.3 Hz, *J* = 1.6 Hz, 1H, C*H*H=CH-COO *(cis)*), 6.09 (dd, *J* = 17.2 Hz, *J* = 10.3 Hz, 1H, CH~2~=C*H*-COO), 6.39 (dd, *J* = 17.2 Hz, *J* = 1.6 Hz, 1H, CH*H*=CH-COO (*trans*)); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, in the presence of PhNHNH~2~) 20.79 (2×CH~3~), 31.86 (2×CH~3~), 43.92 (2×CH~2~), 59.89 (2×*C*(CH~3~)~2~), 66.99 (CH-O-), 128.94 (CO*C*H=CH~2~), 130.84 (COCH=*C*H~2~), 165.95 (C=O).

PdEnCatTOTP30 was purchased from Aldrich. Iodobenzene derivatives and catalysts were purchased from Aldrich, Alfa-Aesar and Fluorochem. The Pd(PPh~3~)~4~ was synthesized according to the known procedure \[[@R38]\]. The experiments were performed in a 25--50 mL round-bottom two necked flask, equipped with a magnetic stirrer and a reflux condenser under anhydrous argon atmosphere (inlet through the top of the condenser equipped with a short drying column packed with drying silica, outlet by a needle placed in a septum in a side neck of the flask). Most of the products were obtained as red solids. TLC was performed on silica gel Merck aluminium roll 5562 or aluminium sheets 5554. Column chromatography was performed using Merck 1.09385.1000 or Zeochem 60 hyd 40--63 μm silica gel (0.040--0.063 mm, 230--400 mesh), respectively. TLC visualisation: UV 254 nm light and/or iodine vapours. MS (EI, 70 eV, *m*/*z*, int. (%)) data were recorded using AMD 604 and Agilent Technologies 5975 B mass spectrometers. HRMS (EI) data were recorded using an AMD 604 mass spectrometer. MS and HRMS (ESI, positive ion, CH~3~OH as a solvent) were recorded using a Micromass LCT apparatus. IR (cm^−1^) data were recorded using a FTIR Jasco 420 spectrometer. ^1^H and ^13^C NMR data were collected using a Varian UNITYplus 200 spectrometer. NMR spectra were performed with a drop of phenylhydrazine (in fact the spectra of corresponding hydroxylamines were recorded) \[[@R49]\].

Cinnamates **5a--i**; general procedure using PdEnCatTOTP30 as a catalyst
-------------------------------------------------------------------------

4-Acryloyloxy-2,2,6,6-tetramethylpiperidin-1-oxyl (**3**, 0.113 g, 0.5 mmol), Aryl iodide (**4a**--**i**, 0.5 mmol), Bu~4~N^+^AcO^−^ (hygroscopic) (0.3 g), PdEnCatTOTP30 (0.0625 g, 0.025 mol, 5 mol %), and toluene (2 mL) were placed in a flask, stirred and heated at 80--100 °C for 20--27 h under argon. The particular temperatures and times of the reactions are summarized in [Table 1](#T1){ref-type="table"}. After approximately 6 h, a second portion of a catalyst (0.0625 g, 0.025 mol, 5 mol %) was added. The progress of the reaction was monitored by TLC (silica, hexane/ethyl acetate 9:1). Upon completion of the reaction, the solids were filtered off, the dark filtrate was concentrated under reduced pressure and subjected to column chromatography (hexane/ethyl acetate 9:1, benzene/ethyl acetate 95:5, benzene/methanol 95:5 as possible mobile phases). The red zone was collected, the eluate was evaporated under reduced pressure to yield red oils (solidified in a refrigerator), or directly red crystals of **5a**--**i**.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E-*phenylacrylate (**5a**)
--------------------------------------------------------------------

42.4%; mp 97--98 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 302 (10, M^+^), 272 (7), 207 (19), 179 (6), 178 (10), 154 (27), 140 (20), 139 (14), 131 (100, ArCH=CHCO), 124 (89), 109 (69), 103 (41), 82 (15), 81 (12), 77 (21), 69 (13), 68 (9), 67 (9), 55 (10), 41 (18); HRMS (EI, 70 eV, *m/z*, int \[%\]): calcd for C~18~H~24~NO~3~: 302.1756, found: 302.1750; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.26 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~), 1.28 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* ~3~)(CH~3~)), 1.74 (t, *J* = 12.0 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.02 (ddd, *J* = 12.8 Hz, *J* = 4.4 Hz, *J* = 1.2 Hz, 2H, H*H*C-CH(O-)-C*H*H), 5.20 (tt, *J* = 11.2 Hz, *J* = 4.3 Hz, 1H, C*H*-OC(=O)), 6.41 (d, *J* = 16.0 Hz, 1H, Ar-CH=C*H*-COO), 7.67 (d, *J* = 16.0 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.87 (2×CH~3~), 31.67 (2×CH~3~), 43.87 (2×CH~2~), 60.46 (2×*C*(CH~3~)~2~), 66.76 (CH-O-), 118.51 (CH), 128.30 (CH), 129.10 (CH), 130.52 (CH), 134.57 (C), 145.00 (CH), 166.68 (C=O); IR (cm^−1^, KBr) 2976, 2937, 1712, 1639, 1450, 1308, 1168, 1008, 978, 859, 765, 709, 685.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(4-methylphenyl)acrylate (**5b**)
------------------------------------------------------------------------------

30.4%, oil; MS (EI, 70 eV, *m*/*z*, int \[%\]) 316 (24, M^+^), 286 (15), 230 (6), 163 (13), 162 (21), 154 (46), 145 (91, ArCH=CHCO), 140 (62), 139 (27), 124 (100), 117 (43), 115 (49), 109 (75), 98 (14), 91 (32), 82 (37), 81 (22), 69 (31), 68 (17), 67 (18), 65 (10), 60 (8), 59 (9), 58 (11), 57 (13), 56 (19), 55 (25), 43 (35), 41 (39); MS (ESI, *m*/*z*, int \[%\]): 340 (15, M + 23 + H), 318 (M + 2H); HRMS (EI, 70 eV, *m*/*z*, int \[%\]): calcd for C~19~H~26~NO~3~: 316.1913, found: 316.1926; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.85 (t, *J* = 12.1 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.02--2.17 (m, 2H, H*H*C-CH(O-)-C*H*H), 2.37 (s, 3H, CH~3~), 5.23 (tt, *J* = 11.1 Hz, *J* = 4.4 Hz, 1H, C*H*-OC(=O)), 6.35 (d, *J* = 15.8 Hz, 1H, Ar-CH=C*H*-COO), 7.64 (d, *J* = 15.8 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~): 21.35 (impurity), 21.69 (2×CH~3~), 23.04 (Ar*C*H~3~), 29.84 (2×CH~3~), 43.01 (2×CH~2~), 62.60 (2×*C*(CH~3~)~2~), 65.67 (CH-O-), 115.32 (impurity), 117.03 (CH), 128.34 (CH), 129.86 (CH), 141.12 (C), 145.37 (CH), 166.73 (C=O), 179.47 (impurity); IR (cm^−1^, film): 2976, 1711, 1635, 1166, 815.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(3,4-dichlorophenyl)acrylate (**5c**)
----------------------------------------------------------------------------------

62.7%; pink crystals, mp 118--120 °C; MS (EI, 70 eV, *m/z*, int \[%\]) 370 (2, M^+^), 201 (40), 199 (64, ArCH=CHCO), 173 (12), 171 (19), 154 (16), 136 (42), 124 (88), 109 (100), 101 (8), 99 (11), 82 (16), 81 (19), 69 (18), 67 (21), 56 (17), 55 (25), 41 (65); MS (ESI, *m/z*, int \[%\]): 395 (20), 393 (90, M + Na), 304 (100); HRMS (ESI): calcd for C~18~H~22~NO~3~Cl~2~Na: 393.0874, found, 393.0890; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.27 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~)), 1.29 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* ~3~)(CH~3~)), 1.75 (t, *J* = 12.0 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.02 (dd, *J* = 12.8 Hz, *J* = 4.4 Hz, 2H, H*H*C-CH(O-)-C*H*H), 5.20 (tt, *J* = 11.3 Hz, *J* = 4.3 Hz, 1H, C*H*-OC(=O)), 6.38 (d, *J* = 15.5 Hz, 1H, Ar-CH=C*H*-COO), 7.40 (d, *J* = 15.5 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.87 (2×CH~3~), 31.54 (2×CH~3~), 43.72 (2×CH~2~), 60.70 (2×*C*(CH~3~)~2~), 67.04 (CH-O-), 117.10 (C), 120.36 (CH), 127.23 (CH), 129.85 (CH), 131.10 (CH), 133.45 (C), 134.59 (C), 142.24 (CH), 166.02 (C=O); IR (cm^−1^, KBr) 2975, 1706, 1638, 1474, 1319, 1267, 1173, 1150, 1206, 979, 822.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(4-methoxyphenyl)acrylate (**5d**)
-------------------------------------------------------------------------------

75.8%; mp 70--74 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 332 (19, M^+^), 302 (6), 284 (2), 267 (5), 246 (4), 178 (32), 161 (100, ArCH=CHCO), 154 (20), 140 (8), 139 (9), 133 (17), 124 (61), 109 (44); MS (ESI, *m*/*z*, int \[%\]): 355 (100, M + Na); HRMS (ESI): calcd for C~19~H~26~NO~4~Na: 355.1760, found, 355.1753; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.24 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~)), 1.25 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* ~3~)(CH~3~)), 1.67 (t, *J* = 11.9 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.00 (ddd, *J* = 11.2 Hz, *J* = 4.4 Hz, *J* = 1.4 Hz, 2H, H*H*C-CH(O-)-C*H*H), 1.67 (t, *J* = 11.9 Hz, 2H, *H*HC-CHOCO-CH*H*), 2.00 (ddd, *J* = 1.4 Hz, *J* = 4.4 Hz, *J* = 11.2 Hz, 2H, H*H*C-CHOCO-C*H*H), 3.83 (s, 3H, OCH~3~), 5.18 (tt, *J* = 11.2 Hz, *J* = 4.4 Hz, 1H, C*H*-OC(=O)), 6.28 (d, *J* = 16.0 Hz, 1H, Ar-CH=C*H*-COO), 7.62 (d, *J* = 16.0 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.79 (2×CH~3~), 31.96 (2×CH~3~), 44.12 (2×CH~2~), 55.57 (OCH~3~), 59.90 (2×*C*(CH~3~)~2~), 66.68 (CH-O-), 114.51 (CH), 116.03 (CH), 127.33, 129.94 (CH), 144.60 (CH), 161.57, 167.02 (C=O); IR (cm^−1^, KBr) 1707, 1632, 1604, 1515, 1290, 1255, 1163, 984, 827.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(2-nitrophenyl)acrylate (**5e**)
-----------------------------------------------------------------------------

76.4%; mp 107--110 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 347 (23, M^+^), 317 (5), 176 (63, ArCH=CHCO), 154 (25), 140 (11), 139 (17), 130 (61), 124 (100), 109 (87), 102 (21); MS (ESI, *m*/*z*, int \[%\]): 370 (100, M + Na); HRMS (ESI): calcd for C~18~H~23~N~2~O~5~Na: 370.1505, found, 370.1492; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.24 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~)), 1.25 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* ~3~)(CH~3~)), 1.69 (t, *J* = 11.8 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.01 (ddd, *J* = 12.0 Hz, *J* = 3.4 Hz, *J* = 1.3 Hz, 2H, H*H*C-CH(O-)-C*H*H), 1.69 (t, *J* = 11.8 Hz, 2H, *H*HC-CHOCO-CH*H*), 2.01 (dtd, *J* = 1.4 Hz, *J* = 3.4 Hz, *J* = 12.0 Hz, 2H, H*H*C-CHOCO-C*H*H), 5.20 (tt, *J* = 11.3 Hz, *J* = 4.3 Hz, 1H, C*H*-OC(=O)), 6.33 (d, *J* = 16.0 Hz, 1H, Ar-CH=C*H*-COO), 8.10 (d, *J* = 16.0 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.82 (2×CH~3~) 31.91 (2×CH~3~) 43.96 (2×CH~2~) 59.84 (2×*C*(CH~3~)~2~) 67.55 (CH-O) 123.60 (CH) 125.14 (CH) 129.34 (C) 130.49 (CH) 130.80 (C) 133.73 (CH) 140.27 (CH) 148.00 (CH) 165.51 (C=O); IR (cm^−1^, KBr) 2977, 1717, 1632, 1523, 1341, 1292, 1272, 1171, 1009, 980, 866, 789, 758.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(3-nitrophenyl)acrylate (**5f**)
-----------------------------------------------------------------------------

99.9%; mp 121--123 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 347 (5, M^+^), 176 (85, ArCH=CHCO), 160 (6), 154 (13), 130 (17), 129 (17), 124 (83), 118 (12), 109 (100), 102 (73), 91 (13), 82 (17), 81 (22), 76 (21), 69 (18), 68 (12), 67 (25), 57 (14), 56 (18), 55 (27), 43 (19). 41 (62); MS (ESI, *m*/*z*, int \[%\]): 370 (100, M + Na); HRMS (ESI): calcd for C~18~H~23~N~2~O~5~Na: 370.1505, found, 370.1489; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~), 1.249 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~)), 1.254 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* ~3~)(CH~3~)), 1.69 (t, *J* = 12.0 Hz, 2H, *H*HC-CHOCO-CH*H*), 2.01 (ddd, *J* = 1.4 Hz, *J* = 4.4 Hz, *J* = 11.2 Hz, 2H, H*H*C-CHOCO-C*H*H), 5.21 (tt, *J* = 11.4 Hz, *J* = 4.4 Hz, 1H, CH-OC(=O)), 6.53 (d, *J* = 16.0 Hz, 1H, Ar-CH=C*H*-COO), 7.69 (d, *J* = 16.0 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.75 (2×CH~3~), 32.05 (2×CH~3~), 44.05 (2×CH~2~), 59.76 (2×*C*(CH~3~)~2~), 67.55 (CH-O-), 121.77 (CH), 122.63 (CH), 124.74 (CH), 130.16 (CH), 133.85 (CH), 136.32 (C), 142.00 (CH), 148.87 (C), 165.83 (C=O); IR (cm^−1^, KBr) 3080, 2971, 1709, 1642, 1526, 1358, 1330, 1191, 983, 813, 671.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(4-nitrophenyl)acrylate (**5g**)
-----------------------------------------------------------------------------

55.3%; mp 148--149 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 347 (19, M^+^), 317 (6), 261 (3), 176 (89, ArCH=CHCO), 160 (7), 154 (19), 140 (14), 139 (15), 130 (24), 124 (100), 109 (90), 102 (29); HRMS (EI, 70 eV, *m*/*z*, int \[%\]): calcd for C~18~H~23~N~2~O~5~: 347.16070, found, 347.16009; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.25 (s, 12H, 4×CH~3~), 1.68 (t, *J* = 12.0 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.00 (dd, *J* = 12.6 Hz, *J* = 4.0 Hz, 2H, H*H*C-CH(O-)-C*H*H), 1.68 (t, *J* = 12.0 Hz, 2H, *H*HC-CHOCO-CH*H*), 2.00 (dd, *J* = 4.0 Hz, *J* = 12.6 Hz, 2H, H*H*C-CHOCO-C*H*H), 5.21 (tt, *J* = 11.3 Hz, *J* = 4.4 Hz, 1H, C*H*-OC(=O)), 6.52 (dd, *J* = 16.0 Hz, *J* = 0.6 Hz, 1H, Ar-CH=C*H*-COO), 7.32 (dd, *J* = 16.0 Hz, *J* = 0.6 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.73 (2×CH~3~), 32.01 (2×CH~3~), 44.02 (2×CH~2~), 59.79 (2×*C*(CH~3~)~2~), 67.62 (CH-O-), 122.89 (CH), 124.37 (CH), 128.54 (C), 128.84 (CH), 140.69 (C), 141.92 (CH), 165.71 (C=O); IR (cm^−1^, KBr) 1705, 1638, 1519, 1344, 1177, 850.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(2-methyl-4-nitrophenyl)acrylate (**5h**)
--------------------------------------------------------------------------------------

88.3%; mp 109--112 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 361 (15, M^+^), 347 (4), 331 (7), 191 (32), 190 (74, ArCH=CHCO), 174 (11), 161 (6), 160 (10), 154 (29), 144 (37), 140 (57), 139 (26), 124 (100), 116 (47), 115 (60), 109 (82), 98 (12), 95 (11), 89 (10), 82 (36), 81 (30), 69 (33), 68 (20), 67 (27), 58 (9), 57 (12), 56 (21), 55 (30), 43 (15), 42 (12), 41 (45); HRMS (EI, 70 eV, *m*/*z*, int \[%\]): calcd for C~19~H~25~N~2~O~5~: 361.1763, found, 361.1761; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.26 (s, 6H, (C*H* ~3~)(CH~3~)CN(OH)C(CH~3~)(C*H* ~3~)), 1.28 (s, 6H, (CH~3~)(C*H* ~3~)CN(OH)C(C*H* ~3~)(CH~3~)), 1.74 (t, *J* = 12.0 Hz, 2H, *H*HC-CH(O-)-CH*H*), 2.03 (ddd, *J* = 11.2 Hz, *J* = 4.4 Hz, *J* = 1.4 Hz, 2H, H*H*C-CH(O-)-C*H*H), 2.51 (ArCH~3~), 5.22 (tt, *J* = 11.3 Hz, *J* = 4.3 Hz, 1H, CH-OC(=O)), 6.42 (d, *J* = 15.9 Hz, 1H, Ar-CH=C*H*-COO), 7.90 (d, *J* = 15.9 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.10 (ArCH~3~), 20.90 (2×CH~3~), 31.66 (2×CH~3~), 43.81 (2×CH~2~), 60.32 (2×*C*(CH~3~)~2~), 67.47 (CH-O-), 121.62 (CH), 123.52 (CH), 125.72 (CH), 127.52 (CH), 128.95 (C), 139.22 (C), 139.93 (C), 140.21 (CH), 165.86 (C=O); IR (cm^−1^, KBr) 1715, 1519, 1347, 1170.

2,2,6,6-Tetramethyl-1-oxyl-4-piperidyl 3-*E*-(2-chloro-4-nitrophenyl)acrylate (**5i**)
--------------------------------------------------------------------------------------

56.2%; mp 107--110 °C; MS (EI, 70 eV, *m*/*z*, int \[%\]) 383 (1), 382 (1), 381 (2, M^+^), 212 (14), 211 (9), 210 (41, ArCH=CHCO), 194 (4), 192 (8), 166 (4), 164 (11), 154 (15), 140 (17), 139 (14), 138 (9), 136 (23), 124 (89), 109 (100), 101 (13), 100 (19), 99 (7), 98 (9), 95 (8), 89 (13), 82 (19), 81 (22), 75 (12), 74 (12), 69 (19), 68 (13), 67 (23), 57 (14), 56 (17), 55 (28), 43 (18), 41 (58); MS (ESI, *m*/*z*, int \[%\]): 404 (15, M + Na), 249 (100), 242 (15); HRMS (ESI): calcd for C~18~H~22~N~2~O~5~ClNa: 404.1115, found, 404.1131; ^1^H NMR (200 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 1.25, 1.27, 1.29 (3s, 12H, 4×CH~3~), 1.75 (m, 2H, *H*HC-CH(O-)-CH*H*), 2.01 (m, 2H, H*H*C-CH(O-)-C*H*H), 5.22 (tt, *J* = 11.3 Hz, *J* = 4.3 Hz, 1H, C*H*-OC(=O)), 6.51 (d, *J* = 16.0 Hz, 1H, Ar-CH=C*H*-COO), 8.03 (d, *J* = 16.0 Hz, 1H, Ar-C*H*=CH-COO); ^13^C NMR (50 MHz, δ, CDCl~3~, TMS, PhNHNH~2~) 20.88 (2×CH~3~), 31.67 (2×CH~3~), 43.75 (2×CH~2~), 60.33 (2×*C*(CH~3~)~2~), 67.72 (CH-O-), 122.22 (CH), 125.02 (CH), 125.58 (CH), 128.53 (C), 128.87 (C), 128.90 (CH), 138.45 (CH), 139.10 (C), 165.31 (C=O); IR (cm^−1^, KBr) 2976, 1712, 1523, 1346, 1330, 1194, 1180, 990.
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